相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。An evidence review of face masks against COVID-19
Jeremy Howard et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Population Decline in COPD Admissions During the COVID-19 Pandemic Associated with Lower Burden of Community Respiratory Viral Infections
Jennifer Y. So et al.
AMERICAN JOURNAL OF MEDICINE (2021)
Impact of social distancing on the spread of common respiratory viruses during the coronavirus disease outbreak
Min-Chul Kim et al.
PLOS ONE (2021)
COVID-19: what is next for public health?
David L. Heymann et al.
LANCET (2020)
Machine learning improves the prediction of febrile neutropenia in Korean inpatients undergoing chemotherapy for breast cancer
Bum-Joo Cho et al.
SCIENTIFIC REPORTS (2020)
Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy
Ye Won Jeon et al.
JOURNAL OF BREAST CANCER (2020)
Pegfilgrastim for primary prophylaxis of febrile neutropenia in breast cancer patients undergoing TAC chemotherapy
Jihyoun Lee et al.
ANNALS OF SURGICAL TREATMENT AND RESEARCH (2018)
Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update
Thomas J. Smith et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
An open-label, randomized, multicenter dose-finding study of once-per-cycle pegfilgrastim versus daily filgrastim in Chinese breast cancer patients receiving TAC chemotherapy
Wei Zhang et al.
MEDICAL ONCOLOGY (2015)
Management of Breast Cancer Patients with Chemotherapy-Induced Neutropenia or Febrile Neutropenia
Caterina Fontanella et al.
BREAST CARE (2014)
Toxicity and quality of life of Korean breast cancer patients treated with docetaxel-containing chemotherapy without primary G-CSF prophylaxis
Jihyoun Lee et al.
BREAST CANCER (2014)
Breast cancer as a systemic disease: a view of metastasis
A. J. Redig et al.
JOURNAL OF INTERNAL MEDICINE (2013)
American Society of Clinical Oncology Identifies Five Key Opportunities to Improve Care and Reduce Costs: The Top Five List for Oncology
Lowell E. Schnipper et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
M. S. Aapro et al.
EUROPEAN JOURNAL OF CANCER (2011)
Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2-Normal, Node-Positive Breast Cancer: BCIRG-005 Trial
Wolfgang Eiermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Pegfilgrastim ± ciprofloxacin for primary prophylaxis with TAC (docetaxel/doxorubicin/cyclophosphamide) chemotherapy for breast cancer.: Results from the GEPARTRIO study
G. von Minckwitz et al.
ANNALS OF ONCOLOGY (2008)
Febrile Neutropenia Evolving Strategies
Michael Ellis
RECENT ADVANCES IN CLINICAL ONCOLOGY (2008)
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review
Nicole M. Kuderer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC):: impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
M. Martin et al.
ANNALS OF ONCOLOGY (2006)
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients
NM Kuderer et al.
CANCER (2006)
分享论文
